TCZ use was associated to improvement in cell cholesterol-related lipoprotein functions, as suggested by a pilot study of ours on RA patients [213], showing that after treatment ABCG1- and SR-BI-mediated CEC are improved, despite HDL serum level stability. The gene discussed is ABCG1; the disease is rheumatoid arthritis.